Transcription factors as therapeutic targets in focal segmental glomerular sclerosis

The Department of the Army Medical Command awarded a $2,455,660 project grant to Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) to support research on "TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS." The period of performance for this award is from September 30, 2022 through September 29, 2026.

The grant is being funded through the Military Medical Research and Development program (CFDA 12.420). This program aims to transform health care for service members and the public through innovative biomedical research that investigates medical solutions for battlefield wounds. Specifically, this award will support Bidmc's research on using transcription factors as potential therapeutic targets for focal segmental glomerular sclerosis, a condition that causes scarring of the kidney's filtering units. The research may help develop new treatments for both service members and civilians suffering from this condition.